Compounds > alpha-aminopyridine
Page last updated: 2024-08-21

alpha-aminopyridine and Carcinogenesis

alpha-aminopyridine has been researched along with Carcinogenesis in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (42.86)24.3611
2020's4 (57.14)2.80

Authors

AuthorsStudies
Gu, L; Lei, C; Li, Y; Lin, X; Liu, C; Lu, B; Prochownik, EV; Zhao, Q; Zhou, F; Zhou, X; Zhu, Y1
Bechard, ME; Bilbao, D; Duryea, J; Kingsley, PJ; Marnett, LJ; McDonald, OG; Roberts, ER; Smalling, RV; Stauffer, SR1
Chow, EK; Hooi, L; Lim, JJ; Rashid, MBMA; Toh, TB1
Crosby, MR; Hudson, WA; Laoharawee, K; Largaespada, DA; Larsson, AT; Mills, LJ; Moriarity, BS; Osum, SH; Peterson, JJ; Pomeroy, EJ; Rahrmann, EP; Rathe, SK; Slipek, NJ; Smeester, BA; Stratton, N; Wang, M; Williams, KB; Yamamoto, K1
Kim, JW; Kim, SJ; Kim, YA; Kim, YK; Lee, HY; Lee, SH; Yeo, CD1
Bai, Y; Deng, L; Ding, M; Lu, D; Shao, YW; Wu, X; Yang, Y; Yu, R1
Affolter, T; Appleman, V; Brooun, A; Charest, A; Deng, YL; Engstrom, LD; Falk, MD; Fantin, VR; Hu, W; Jiang, P; Johnson, TW; Lam, J; Lappin, PB; Li, Q; Liu, W; McDonnell, SR; McTigue, M; Nichols, T; Smeal, T; Timofeevski, S; West, M; Wong, KA; Zou, HY1

Other Studies

7 other study(ies) available for alpha-aminopyridine and Carcinogenesis

ArticleYear
USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1.
    Cell reports, 2021, 12-28, Volume: 37, Issue:13

    Topics: Aged; Aged, 80 and over; Aminopyridines; Animals; B7-H1 Antigen; Carcinogenesis; Case-Control Studies; Colorectal Neoplasms; Endopeptidases; Female; Humans; Immune Checkpoint Inhibitors; Lipogenesis; Male; Mice, Inbred C57BL; Middle Aged; Mitogen-Activated Protein Kinase 1; Phosphorylation; Pyrroles; Reactive Oxygen Species; Ubiquitination; Vesicular Transport Proteins

2021
Aminopyridine analogs selectively target metastatic pancreatic cancer.
    Oncogene, 2022, Volume: 41, Issue:10

    Topics: Aminopyridines; Carcinogenesis; Histones; Humans; Pancreatic Neoplasms; Phosphogluconate Dehydrogenase; Prodrugs

2022
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Journal of hepatology, 2020, Volume: 72, Issue:1

    Topics: Aminopyridines; Animals; beta Catenin; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; Dimethyl Sulfoxide; Female; Humans; Hyaluronan Receptors; Janus Kinases; Liver Neoplasms; Male; Mice; Mice, Transgenic; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Transfection; Transplantation, Homologous; Tumor Burden

2020
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
    Bone, 2020, Volume: 136

    Topics: Aminopyridines; Animals; Carcinogenesis; Macrophage Colony-Stimulating Factor; Mice; Osteosarcoma; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor

2020
Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model.
    European journal of pharmacology, 2017, Oct-05, Volume: 812

    Topics: Aminopyridines; Animals; Benzamides; Benzo(a)pyrene; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Lung Neoplasms; Mice; Neovascularization, Pathologic

2017
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.
    Clinical lung cancer, 2019, Volume: 20, Issue:3

    Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2019
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Mar-17, Volume: 112, Issue:11

    Topics: Aminopyridines; Animals; Carcinogenesis; Cell Proliferation; Crizotinib; Crystallography, X-Ray; Disease Models, Animal; Drug Resistance, Neoplasm; Glioma; Humans; Lactams; Lactams, Macrocyclic; Mice; Models, Molecular; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Signal Transduction

2015